AlphAIalphai — Financial news for AI agents
finance.yahoo.comJUL 285 min read$TLRY

Tilray Brands, Inc. (TLRY) Reports Q4 Loss, Beats Revenue Estimates

Tilray Brands (TLRY) reported a Q4 adjusted loss of $0.43 per share, compared with the Zacks Consensus Estimate loss of $0.02, versus a year-ago profit of $0.20 per share. Revenue rose to $281.71 million, above consensus by 9.14%. Ahead, consensus calls for -$0.19 EPS on $259.97 million revenue next quarter.

Original reporting
finance.yahoo.com
Published Jul 28, 2026, 11:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 29, 2026, 3:02 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefEarnings
Primary signal
$TLRY
Bearish
medium confidence
Mentioned
$TLRY
Relevance
7/10
alphai data visualization · based on finance.yahoo.com
Decision brief

The 30-second read

$TLRYBearishMed
01

Why it matters

EPS materially missed consensus while revenue beat, so the market’s next decision point is whether management commentary and forward estimate revisions offset the EPS disappointment.

02

Market read

This is a fresh earnings print with a large EPS miss and a revenue beat, making it actionable for positioning into the earnings call and any immediate estimate revisions.

03

What to watch

The article emphasizes adjusted EPS and non-recurring items; traders should focus on the earnings call for recurring profitability drivers and any changes to the current-quarter and full-year consensus (currently negative EPS).

Relevance 7/10Novelty 6/10Timing: after-hours/late-day reaction to the just-released Q4 results and ahead of the earnings call commentary.

Background

The piece summarizes Tilray’s Q4 adjusted results versus Zacks Consensus and discusses how estimate revisions and the Zacks Rank may relate to near-term stock movement.

Company-level read

Ticker impact

$TLRYBearishMedium confidence
Context

Tilray reported Q4 adjusted EPS of -$0.43 versus a -$0.02 consensus, while revenue of $281.71M beat estimates by 9.14%.

Expected impact

Near-term volatility likely, with direction dependent on the earnings call commentary and whether forward EPS estimates improve from current consensus.

Evidence & confidence

The article provides a large negative EPS surprise (-2,050%) and notes stock reaction depends on management commentary; it also flags a Zacks Rank #3 (Hold) and mixed estimate revisions ahead of the print.

Market effects

Sector

As a medical-products/consumer staples-adjacent cannabis name, Tilray’s earnings trajectory can influence sentiment toward high-beta cannabis operators, but the article is company-specific.

Regional

No specific regional spillover beyond general risk appetite for US-listed cannabis equities.

Global

Limited global read-through; the disclosed facts are confined to Tilray’s quarterly performance and consensus outlook.

Counterpoint

What could challenge this read

The revenue beat (+9.14%) and history of topping revenue consensus in recent quarters could support a rebound if management frames cost control and margin trajectory convincingly.

Key entities

  • public_company
    Tilray Brands, Inc.

    Subject of the article, reporting Q4 adjusted EPS and revenue versus consensus and discussing forward consensus expectations.

  • estimate_source
    Zacks Consensus Estimate

    The benchmark used for EPS and revenue comparisons in the article.

  • rating
    Zacks Rank #3 (Hold)

    The article’s stated pre-release rating based on estimate revisions.

Read at source← All news

Related articles

AUG 7
$TLRYMed

Tilray Brands (TLRY) Is Up 5.7% After Narrower Loss, ESOP Shelf Filing and M&A Signal

Tilray Brands reported Q4 sales of US$281.71 million and full-year sales of US$915.45 million for the year ended May 31, 2026, with a substantially smaller net loss than the prior year. The company also filed a US$47.69 million shelf registration for 11,355,231 common shares tied to its ESOP. Management said at-the-market equity proceeds may fund acquisitions, including deals like BrewDog.

simplywall.st7 min
JUL 30
$TLRYMed

Tilray Brands Q4 Earnings Call Highlights

Tilray Brands (NASDAQ: TLRY) reported fiscal 2026 results on its Q4 earnings call. Net loss narrowed to $105.2M ($1.09/share) from about $2.2B in fiscal 2025. Adjusted net income rose 87% to $12.2M. Cannabis and distribution revenue grew, BrewDog added beverage revenue, and Tilray guided adjusted EBITDA of $68M to $75M for fiscal 2027.

yahoo.com6 min
JUL 29
$TLRYMed

Tilray Brands reports record US$915.5M revenue in Fiscal 2026

Tilray Brands reported record fiscal 2026 revenue of US$915.5M, up 11% from US$821.3M, driven by cannabis, beverage, distribution and wellness. Beverage net revenue rose 6% to US$254.0M, with Q4 beverage revenue up 61% to US$105M. Adjusted EBITDA increased to US$61.1M. Tilray completed a £33M BrewDog acquisition in March. It forecasts fiscal 2027 adjusted EBITDA of US$68M to US$75M.

foodbusinessmea.com4 min
JUL 29
$TLRYMedAI 8/10

Tilray Brands Q4 revenue beats estimates by 10.7%, shares rise 2.23%

Tilray Brands reported Q4 net revenue of $281.7 million for the period ended May 31, up 10.7% versus the $254.53 million consensus estimate, and shares rose 2.23% to $4.12 after hours. Adjusted EPS was $0.05, missing the $0.21 consensus. For FY26, net revenue rose 11% to $915.5 million; adjusted EBITDA increased to $61.1 million.

scanx.trade4 min
JUL 28
$TLRYMed

Tilray Brands Q4 Results: Adj. EPS beats estimate, sales up 25%

Tilray Brands (NASDAQ: TLRY) reported Q4 adjusted EPS of $0.05, versus a $(0.01) analyst consensus, and quarterly sales of $281.714 million versus $246.377 million expected. Sales rose 25.47% year over year to $281.714 million, while adjusted EPS fell 75% from $0.20. The company also noted Revolver’s Blood & Honey spirits launch in Texas.

scanx.trade5 min